Barrons
01 Oct 2026, 11:40 UTC · 2h ago
Verdict
Headline leans bearish. We score FOGN −0.40 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.40moderately bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Foghorn Therapeutics' cancer-drug partnership with Eli Lilly has been dissolved.
Newheadline published 2026-10-01
So whatLoss of partnership milestones and funding will likely force a downward revision of revenue estimates for FY2027.
More negative than 99% of claims this week
Foghorn is slashing 40% of its jobs.
Continue reading
5 related stories
More negative than 69% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Newheadline published 2026-10-01
So whatImmediate payroll reduction aims to lower quarterly burn rates to extend the current cash runway.
More negative than 95% of claims this week
Foghorn and Eli Lilly do not plan any future collaborations.
Newarticle published 2026-10-01
More negative than 85% of claims this week
Which stocks this story touches
More negative than 69% of ticker scores this week
The company is ending a strategic cancer-drug partnership with a major pharmaceutical peer.
More negative than 60% of ticker scores this week
The company is dissolving a collaboration, though it has less relative impact on a company of its size.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
6h ago
—
No price for FOGN right now — the quote feed didn't answer.
FOGN chart →
